"The problem is that this pre-fusion structure is so fragile and ... ready to push open the RSV F protein at the slightest perturbation, like a spring-loaded transformer. "This is an incredible ...

First, they must enter the host cells, which RSV does using its fusion (F) protein. Vaccines induce antibodies that bind to pathogens. Neutralizing antibodies bind to crucial sites, such as part ...

Palivizumab (Synagis; MedImmune/Abbott) is a humanized murine monoclonal antibody against the RSV fusion protein that prevents the spread of virus to the lower respiratory tract 2. It was approved ...

which used McLellan and Graham’s research to stabilize the RSV fusion protein and enable the body to develop strong antibodies against it, according to UT. “Getting into structure-based vacc ...

The acquisition focuses on sisunotavir, an RSV fusion inhibitor that UK-based ReViral ... including a follow-up RSV candidate targeting the viral N protein that is in phase 1 testing.

Palivizumab injection is used to prevent serious lung infection in children and babies caused by respiratory syncytial virus ...